Shilpa Medicare Gets SEC Nod for OERIS™ Launch in India

Shilpa Medicare Ltd (SHILPA) Regulatory Update: Company has received final approval from SEC for marketing authorization of OERIS™ (Ondansetron Extended‑Release Injection, 100 mg/ml). This is the first extended‑release formulation providing antiemetic action for up to 120 hours, with plans for commercial launch in India. 📊 Key Highlights Product: OERIS™ (Ondansetron ER Injection, 100 mg/ml) Indication: Antiemetic therapy (prevents nausea/vomiting) Duration: Up to 120 hours extended release Approval: SEC marketing authorization Launch: Planned in India 📌 SWOT Analysis Strengths First‑in‑class extended‑release antiemetic in India. Strong R&D capabilities in oncology and supportive care. Regulatory approval enhances credibility. Weaknesses Dependence on oncology supportive care segment. Pricing pressures in Indian generics market. Opportunities Rising demand for antiemetic therapies in chemotherapy. Potential for global expansion of OERIS™. Strengthened specialty portfolio in injectables. Threats Competition from multinational pharma players. Regulatory hurdles in export markets. Risk of generic substitutes impacting margins. 🏭 Fundamentals Snapshot (FY26) Revenue: ~₹1,850 crore EBITDA Margin: ~18% PAT: ~210 crore Debt-to-Equity: ~0.4 Capex Plan: Focused on oncology APIs and formulations